ClinicalTrials.gg
CompletedNCT06197789Updated Jan 9, 2024

Safety and Efficacy Study of TPX-105 for Correction of Nasojugal Groove

A Phase 3 interventional study of TPX-105 and Placebo in Tear Trough Eyelid Deformity, sponsored by Tego Science, Inc.. Completed at 4 sites in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Tego Science, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2021, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Nasojugal groove correction is possible through surgical correction procedures, however, due to risks in safety and drawbacks not being able to be done on the young or after surgical procedure, dermal fillers which have the possibility of granulomatous allergic reaction and surface elevation. Therefore, there is a need for a safer procedure for nasojugal groove correction. This study evaluates the safety and efficacy of Autologous human dermal fibroblasts (TPX-105) used for the correction of nasojugal groove. The primary outcome is the improvement of nasojugal groove evaluated by an independent evaluator after administration of TPX-105 at week 24. Secondary outcomes include the improvement of nasojugal groove at week 4 and 12, severity change from baseline at week 4, 12 and 24 evaluated by an independent evaluator, and overall appearance improvement rate rated by subjects using Global Aesthetic Improvement Scale (GAIS) at week 4, 12, 24 and 48.

02

Conditions studied

  • Tear Trough Eyelid Deformity
03

In context

Lead sponsor

Tego Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must;

  1. Be 19 years old or older.
  2. Have confirmed nasojugal groove severity equal to or more than "Moderate" (severity, grade 3) at subject assessment and want correction.
  3. Consent to undergo skin on unexposed areas for manufacture of test product.
  4. Fully understand the study and voluntarily sign the for participation in the study.

Exclusion criteria

Exclusion Criteria:

Participants with any of the following conditions will be excluded unless stated otherwise;

  1. Unsuitable for skin .
  1. Have prior medical history of the following at the time of screening.
  1. Keloids
  2. Chronic skin diseases (psoriasis, atopic dermatis)
  3. Genetic disorders that affect fibroblasts or collagen (ex. achondroplasia, osteogensis imperfecta, etc.)
  4. disease
  5. (HIV) positive
  6. Coagulopathy
  7. Basal cell carcinoma or history of malignant tumors within the last 5 years
  1. Have any of the following comorbidities at screening.
  1. Inflammatory lesions or infectious diseases in the nasojugal groove region
  2. Wounds, scars, or skin disorders that may affect efficacy assessment
  3. Subjects who require continuous administration (2 weeks or more) of
  4. Acute chronic infectious diseases
  5. Subjects with bleeding requiring medical intervention including blood transfusions
  1. Subjects who have a medical history of the following at the time of screening.
  1. Surgical procedures or surgeries such as fillers or fat grafting on nasojugal groove or tear through deformity.
  2. Surgical procedures or wrinkle corrections around the eyes within 24 weeks from screening. (Ex. botulinum toxin injection, face lift surgery, soft tissue augmentation, semi-intercalated peel, dermal photorejuvenation, or etc.)
  1. Subjects who have received anti- drugs and anticoagulants within 7 days prior to skin biopsy.
  1. Subjects with planned facial cosmetic surgery (facial fillers, photorejuvenation, chemical/mechanical peeling) or facial massages during the duration of the study.
  1. Subjects who have allergies to drug composition or manufacturing ingredients (bovine proteins, gentamicin, etc.)
  1. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of * suggested in this study.

*Hormonal contraceptives (oral, transplanted, etc.), intrauterine device, double-barrier method (condom, diaphragm, or cervical occlusive cap with spermicide), surgically sterile partner, etc.

  1. Have participated in other clinical trials and received investigational agents within 4 weeks of this study.
  1. Be deemed inadequate for the study by investigators. (Serious heart disease, liver disease, kidney disease, etc.)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    TPX-105

    Autologous human dermal fibroblasts

    Biological: TPX-105

  • Sham comparator
    Placebo

    Suspension media

    Biological: Placebo

Interventions

  • BiologicalTPX-105

    Subjects will be administered with autologous fibroblasts through injection

    Also known as: Autologous human dermal fibroblasts

  • BiologicalPlacebo

    Subjects will be administered with Placebo through injection

06

What researchers measure

Primary outcomes

  1. Improvement Rate from Baseline

    Improvement rate of nasojugal groove from baseline will be evaluated by a independent evaluator based on pictures taken at week 24 after administration of investigational product. \*Improvement rate of nasojugal groove definition: With at least a 2-grade decrease

    Time frame: 24 weeks

Secondary outcomes

  1. Improvement Rate from Baseline

    Improvement rate of nasojugal groove from baseline evaluated by an independent evaluator based on pictures taken at week 4 and 12 after administration of investigational product.

    Time frame: 4, 12 weeks

  2. Severity Grade Change from Baseline

    Severity grade change from baseline evaluated by an independent evaluator based on pictures taken at week 4, 12 and 24 after administration of investigational product.

    Time frame: 4, 12, 24 weeks

  3. Overall Appearance Improvement Percentage (%)

    Overall appearance improvement percentage (%) rated by subjects using GAIS\* at week 4, 12, 24 and 48 after administration of investigational product. \*In the case of overall appearance improvement rate using GAIS being +2 points (Much Improved) or +1 (Improved)

    Time frame: 4, 12, 24, 48 weeks

07

Study locations

4 sites
  • Soonchunhyang University Hospital Bucheon
    Bucheon, 14584, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • The Catholic University of Korea, Seoul ST. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jun 2023, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
Jan 9, 2024
StartActual
Aug 18, 2021
Primary completionActual
Jun 5, 2023
CompletionActual
Oct 18, 2023
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06197789
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Aug 18, 2021
Primary completion
Jun 5, 2023
Completion
Oct 18, 2023
Last update
Jan 9, 2024

Study contacts

Ho-yun Jun
principal investigator · Kyungpook National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion